Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

135,590 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Updated Overall Survival and Exploratory Analysis From Randomized, Phase II EVAN Study of Erlotinib Versus Vinorelbine Plus Cisplatin Adjuvant Therapy in Stage IIIA Epidermal Growth Factor Receptor+ Non-Small-Cell Lung Cancer.
Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, Chen C, Mao W, Liu W, Liu J, Zhang L, Ma H, Li Q, Yang Y, Liu Y, Chen H, Zhang Z, Zhang B, Wang C. Yue D, et al. Among authors: liu j, liu y, liu w. J Clin Oncol. 2022 Dec 1;40(34):3912-3917. doi: 10.1200/JCO.22.00428. Epub 2022 Aug 26. J Clin Oncol. 2022. PMID: 36027483 Clinical Trial.
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, Chen C, Mao W, Liu W, Liu J, Zhang L, Ma H, Li Q, Yang Y, Liu Y, Chen H, Wang C. Yue D, et al. Among authors: liu j, liu y, liu w. Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24. Lancet Respir Med. 2018. PMID: 30150014 Clinical Trial.
[Epidemiological characteristic and current status of surgical treatment for esophageal cancer by analysis of national registry database].
Mao YS, Gao SG, Wang Q, Shi XT, Li Y, Gao WW, Guan FS, Li XF, Han YT, Liu YY, Liu JF, Zhang K, Liu SY, Fu XN, Fang WT, Chen LQ, Wu QC, Xiao GM, Chen KN, Jiao GG, Zhang SJ, Mao WM, Rong TH, Fu JH, Tan LJ, Chen C, Xu SD, Guo SP, Yu ZT, Hu J, Hu ZD, Yang YK, Ding NN, Yang D, He J. Mao YS, et al. Among authors: liu yy, liu sy, liu jf. Zhonghua Zhong Liu Za Zhi. 2020 Mar 23;42(3):228-233. doi: 10.3760/cma.j.cn112152-20191112-00729. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 32252202 Chinese.
Chinese expert consensus on mediastinal lymph node dissection in esophagectomy for esophageal cancer (2017 edition).
Li H, Fang W, Yu Z, Mao Y, Chen L, He J, Rong T, Chen C, Chen H, Chen K, Du M, Han Y, Hu J, Fu J, Hou X, Gong T, Li Y, Liu J, Liu S, Tan L, Tian H, Wang Q, Xiang J, Xu M, Ye X, You B, Zhang R, Zhao Y; Society of Esophageal Tumor, Chinese Anti-Cancer Association. Li H, et al. Among authors: liu j, liu s. J Thorac Dis. 2018 Apr;10(4):2481-2489. doi: 10.21037/jtd.2018.03.175. J Thorac Dis. 2018. PMID: 29850156 Free PMC article. Review. No abstract available.
Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China.
Yang Y, Tan L, Hu J, Li Y, Mao Y, Tian Z, Zhang B, Ma J, Li H, Chen C, Chen K, Han Y, Chen L, Liu J, Yu B, Yu Z, Li Z; Esophageal Cancer Committee of Chinese Anti-Cancer Association. Yang Y, et al. Among authors: liu j. Dis Esophagus. 2022 Nov 15;35(11):doac031. doi: 10.1093/dote/doac031. Dis Esophagus. 2022. PMID: 35649396
135,590 results
You have reached the last available page of results. Please see the User Guide for more information.